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Abstract
Background: Clinical practice guidelines provide separate recommendations for different diseases that may be
prevented or treated by the same intervention. Also, they commonly provide recommendations for entire populations
but not for individuals. To address these two limitations, our aim was to conduct benefit-harm analyses for a wide
range of individuals using the example of low dose aspirin for primary prevention of cardiovascular disease and cancer
and to develop Benefit-Harm Charts that show the overall benefit-harm balance for individuals.
Methods: We used quantitative benefit-harm modeling that included 16 outcomes to estimate the probability that
low dose aspirin provides more benefits than harms for a wide range of men and women between 45 and 84 years of
age and without a previous myocardial infarction, severe ischemic stroke, or cancer. We repeated the quantitative
benefit-harm modeling for different combinations of age, sex, and outcome risks for severe ischemic and hemorrhagic
stroke, myocardial infarction, cancers, and severe gastrointestinal bleeds. The analyses considered weights for the
outcomes, statistical uncertainty of the effects of aspirin, and death as a competing risk. We constructed Benefit-Harm
Charts that show the benefit-harm balance for different combinations of outcome risks.
Results: The Benefit-Harm Charts (http://www.benefit-harm-balance.com) we have created show that the benefit-harm
balance differs largely across a primary prevention population. Low dose aspirin is likely to provide more benefits than
harms in men, elderly people, and in those at low risk for severe gastrointestinal bleeds. Individual preferences have a
major impact on the benefit-harm balance. If, for example, it is a high priority for individuals to prevent stroke and
severe cancers while severe gastrointestinal bleeds are deemed to be of little importance, the benefit-harm balance is
likely to favor low dose aspirin for most individuals. Instead, if severe gastrointestinal bleeds are judged to be similarly
important compared to the benefit outcomes, low dose aspirin is unlikely to provide more benefits than harms.
Conclusions: Benefit-Harm Charts support individualized benefit-harm assessments and decision making. Similarly,
individualized benefit-harm assessments may allow guideline developers to issue more finely granulated
recommendations that reduce the risk of over- and underuse of interventions. The example of low dose aspirin for
primary prevention of cardiovascular disease and cancer shows that it may be time for guideline developers to provide
combined recommendations for different diseases that may be prevented or treated by the same intervention.
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Background
Consider a 60-year-old woman who comes to her general
practitioner’s office and asks if she should take a low dose
aspirin to prevent myocardial infarction (MI) or cancer.
She has never had a cardiovascular event or cancer before,
eats vegetables regularly, and is physically active. But she
is a smoker, takes antihypertensive medication (current
systolic blood pressure of 145 mmHg), has total choles-
terol of 170 mg/dL, and HDL cholesterol of 55 mg/dL.
The general practitioner determines the 10-year risks for
both an MI [1] and stroke to be around 6 % [2] and for
colorectal cancer to be around 2 % [3]. Uncertain
about what to recommend to the patient, the general
practitioner consults some guidelines on primary pre-
vention of cardiovascular disease (CVD) and cancer.
Table 1 shows that the World Health Organization
advises against low dose aspirin if the 10-year risk of
an MI is below 30 % [4], the European Society of
Cardiology [5] advises against low dose aspirin for all
individuals, while the United States Preventive Services
Task Force (USPSTF) [6] recommends aspirin if the
risk is ≥8 % in women, because the benefit of lower-
ing the risk of stroke outweighs the risk of major
gastrointestinal (GI) bleeds. To date, the USPSTF rec-
ommends against aspirin for the prevention of colo-
rectal cancer [7].
Table 1 Selected recommendations on low dose aspirin for primary prevention of CVD and colorectal cancer
Disease outcome Organization Recommendation and assumptions made
Cardiovascular disease European Society of Cardiology [5] Aspirin or clopidogrel cannot be recommended in individuals without
cardiovascular or cerebrovascular disease due to the increased risk of
major bleeding. (Class of recommendation III = is not recommended;
level of evidence weak)
No details on assumptions or on how benefit-harm assessment was done
Cardiovascular disease World Health Organization [4] − Coronary heart disease 10-year risk <10 %. For individuals in this risk
category, the harm caused by aspirin treatment outweighs the
benefits. Aspirin should not be given to individuals in this low-risk
category. (1++, A)
− Coronary heart disease 10-year risk 10 to <20 %. For individuals in
this risk category, the benefits of aspirin treatment are balanced by
the harm caused. Aspirin should not be given to individuals in this
risk category. (1++, A)
− Coronary heart disease 10-year risk 20 to <30 %. For individuals in
this risk category, the balance of benefits and harm from aspirin
treatment is not clear. Aspirin should probably not be given to
individuals in this risk category. (1++, A)
− Coronary heart disease 10-year risk ≥30 %. Individuals in this risk
category should be given low dose aspirin. (1++, A)
No details on assumptions or on how benefit-harm assessment was done.
Cardiovascular disease US Preventive Services Task Force [6] Encourage men age 45 to 79 years to use aspirin when the potential
benefit of a reduction in MI outweighs the potential harm of an
increase in gastrointestinal hemorrhage. (“A” recommendation)
The reduction in MI outweighs the potential harm of an increase in
gastrointestinal hemorrhage:
− 45–59 year old if ≥4 % 10-year risk of coronary heart disease
− 60–69 year old if ≥9 % 10-year risk of coronary heart disease
− 70–79 year old if ≥12 % 10-year risk of coronary heart disease
Assumptions for benefit-harm assessment:
− Equal weights given to coronary heart disease, gastrointestinal
hemorrhage, and hemorrhagic stroke
− 10-year risk for coronary heart disease considered from 0–20 %
− Average risk per age category considered gastrointestinal hemorrhage
and hemorrhagic stroke
− Ischemic stroke not considered
− No competing risks considered
Colorectal cancer US Preventive Services Task Force [7] The USPSTF recommends against the routine use of aspirin and
nonsteroidal anti-inflammatory drugs to prevent colorectal cancer in
individuals at average risk for colorectal cancer.
Puhan et al. BMC Medicine  (2015) 13:250 Page 2 of 11
This vignette illustrates the challenge of making
(preventive) treatment recommendations for individuals
and the disagreement among guidelines. In recent years,
advancements were made in the development of
evidence-based clinical practice guidelines. Major guide-
line developers and groups like the USPSTF or the
Grading of Recommendations Assessment, Development
and Evaluation (GRADE) Working Group strongly ad-
vocate to first systematically review the evidence on
the benefits and harms of interventions and, in a second
and separate step, to develop recommendations in a trans-
parent way [8, 9]. Nevertheless, even if guidelines are
based on high-quality systematic reviews and meta-
analyses and follow GRADE or similar guidance, clinical
practice guidelines and regulatory agencies sometimes dis-
agree, as the example of low dose aspirin for cardiovascu-
lar primary prevention shows (Table 1) [6, 10, 11].
There are reasons for such disagreement among guide-
lines. Although many guidelines are now based on
systematic reviews, few guideline developers use quanti-
tative methods to estimate the benefit-harm balance of
interventions [12, 13]. Also, drawing conclusions and is-
suing population-level recommendations just based on
systematic reviews are problematic for some clinical
questions, such as aspirin for cardiovascular primary
prevention, because population-level recommendations
are based on average outcome risks and do not reflect
preferences of individuals [14–16], which may lead to
over- and undertreatment [17, 18]. This may contribute
to the generally rather low adherence to guidelines,
along with other factors that make the transfer of know-
ledge into practice challenging [19, 20].
Compared to guidelines that make recommendations
for entire populations, would it not be preferable to have
treatment recommendations that are individualized
through a patient’s own risks and preferences? And
would it not be preferable to have more holistic guide-
lines on preventative measures that have an impact on
more than one disease?
Typically, recommendations are organized separately
by disease or medical specialty, and the USPSTF is
currently developing or updating its three (separate)
guidelines on aspirin for primary prevention of car-
diovascular, disease, colorectal cancer, and other can-
cers [21]. Some have already argued that it may be
time to move to guidelines that span across different
diseases, which may be prevented by a common pre-
ventative measure such as aspirin [22]. To address
these two limitations, our aim was to conduct
benefit-harm analyses for a wide range of individuals
using the example of low dose aspirin for primary
prevention of CVD and cancer and to develop Benefit-
Harm Charts that show the overall benefit-harm balance
for individuals.
Methods
Selection of approach for benefit and harm assessment
We outlined a selection process for choosing a par-
ticular approach for a quantitative assessment of bene-
fits and harms to illustrate benefit-harm balance in
our previous work [23–25]. For this study, we selected
the Gail/National Cancer Institute (NCI) approach as
the multidimensional approach because it can consider
risks of multiple benefit and harm outcomes, treat-
ment effects on these risks, competing risks, and im-
portance of outcomes (determined by patient outcome
preferences, and when not available, by survival rates
(for example, 5-year survival) and it summarizes all in-
formation in a number (benefit-harm index) [17]. This
approach also provides a probability of net benefit,
which captures major sources of informational uncer-
tainty (see also the section on statistical analysis). In
prior work [26], we compared this approach to the
number needed to treat (NNT) approach, which is a
well-known and established approach, and showed the
Gail/NCI approach’s superiority in situations where
there is more than an average benefit and an average
harm outcome and where there are competing risks
(such as death from other causes).
Selection of data sources
For a quantitative benefit-harm assessment, several sources
of evidence on treatment effects, risks of outcomes, and
preferences for these outcomes are needed. We selected
the following data sources:
a) Treatment effects: We used a recently updated
meta-analysis of nine RCTs for the effect estimates of
aspirin for primary prevention on the outcomes of MI
and severe ischemic stroke (benefit outcomes) and on
severe hemorrhagic stroke and severe GI bleeds [14].
The pooled relative risk for aspirin versus placebo was
0.86 (95 % confidence interval 0.74,1.00) for MI, 0.87
(0.73,1.02) for severe ischemic stroke, 1.35 (1.01,1.81) for
severe hemorrhagic stroke, and 1.62 (1.31,2.00) for
severe GI bleeds. We assumed a homogeneous treat-
ment effect across the male and female populations
since current evidence does not suggest heterogeneity of
(relative) treatment effects [14]. A previous meta-
analysis by the same authors formed the basis of recom-
mendations of the most recent USPSTF statement on
the benefits and harms of aspirin for cardiovascular pri-
mary prevention [6, 27].
For cancers, we used the summary measures of a
meta-analysis of RCTs that assessed the effect of aspirin
on long-term cancer incidence [28]. The pooled relative
risk for aspirin versus placebo was 0.58 (0.44,0.78) for
colorectal cancer, 0.55 (0.23,1.34) for biliary cancer,
0.51 (0.31,0.83) for esophageal cancer, 0.77 (0.49,1.22)
for gastric cancer, 1.17 (0.50,2.71) for breast cancer,
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0.84 (0.69,1.03) for lung cancer, 0.77 (0.59,1.01) for
prostate cancer, 0.92 (0.66,1.29) for hematological
cancer, 0.91 (0.59,1.40) for pancreatic cancer, 0.91
(0.54,1.51) for bladder cancer, 1.04 (0.40,2.73) for
gynecological cancer, and 0.88 (0.48,1.61) for renal
cancer. Some of the 95 % confidence intervals were
wide and crossed 1.0 and the statistical models con-
sidered such statistical uncertainty.
b) Outcome risks: We stratified the analyses for men
and women and four age categories since these two vari-
ables have a substantial effect on the risks of the out-
comes and on all-cause death as a competing risk. We
considered five risk categories both for MI and severe
GI bleeds while we used age- and sex-specific outcome
risks (that is, only one risk per age and sex category) for
all other outcomes (severe ischemic stroke [29],
hemorrhagic stroke [30], 12 different cancers [31], and
death [32]). For each of the resulting combinations of
outcome risks (2sex *4age *5MI *5gastrointestinal bleeds = 200)
we repeated the benefit-harm analyses.
c) Weights for outcomes (importance): We searched
for studies that elicited patient preferences for the out-
comes using PubMed and the terms “patient preference”,
“aspirin”, and “cost-benefit analysis”, as well as the
“related articles” function. We identified one study
that measured the preferences of participants that had
not experienced cardiovascular events (primary pre-
vention population) [15]. We also searched the Cost
Effectiveness Analysis Registry of Tufts University
[33] but did not identify additional studies from a pri-
mary prevention population. However, we did not find
any preference-eliciting surveys on both cardiovascu-
lar and cancer outcomes, which would inform us
about the relative importance of cardiovascular and
cancer outcomes as needed for our analyses. Instead,
and as an anchor for individual preferences, we used
the 5-year survival rates of each of the outcomes and
assigned a weight of 1.0 for outcomes with a 5-year
survival rate of <50 %, 0.5 for those with 5-year sur-
vival rates of 50–90 %, and 0.1 for outcomes with a
5-year survival rate of >90 % (Table 2 [34–37]). We
must emphasize that there is a wide variability of
how people perceive the importance of outcomes. This is
why we developed a website [http://www.benefit-harm-
balance.com] where we illustrate how much different
combinations of weights (according to individual outcome
preferences) affect the benefit-harm balance.
Statistical analysis
For each of the combinations of outcome risks we used
the Gail/NCI approach to estimate the benefit-harm bal-
ance. We first calculated the number of expected events
(N) without aspirin for each of the 16 outcomes per
10,000 subjects over 10 years based on an exponential
model that assumed a constant hazard rate over 10 years
and adjusted for competing risks (here all-cause death).
We then calculated the corresponding number of events
with aspirin prevention, taking into account the treatment
effects of aspirin from the meta-analysis. We calculated
the difference in events between individuals with and
without taking aspirin as an absolute measure of the pre-
ventive effect. We then calculated the benefit-harm index
as the sum of differences in events for each outcome using
the weights described above. To take into consideration
the statistical uncertainty of the estimates for the treat-
ment effects of aspirin, we performed simulations with
100,000 repetitions where we modeled treatment effects
(log relative risk) using a normal distribution and obtained
the probability that aspirin is beneficial as the proportion
of index estimates (out of the 100,000 repetitions) that are
positive [17, 38]. We assumed that outcome risks for
MI and severe GI bleeds follow a uniform distribution
within each risk category. We did not consider that as-
pirin may be discontinued after the occurrence of a
bleed. As explained above, we repeated this analysis
200 times (that is, 200 simulations with 100,000 repeti-
tions each) in order to get estimates of the benefit-
harm balance for each of the 200 combinations of risk
profiles. The simulations were done using R statistical
software version 3.0.1 [39], and the codes are available on
request. It took 25 s to run one simulation (100,000 repe-
titions for one combination of outcome risks) on a stand-
ard laptop (HP EliteBook 840).
Table 2 Weights assigned to outcomes included in the
benefit-harm analyses of low dose aspirin for primary
prevention of cardiovascular disease and colorectal cancer
Outcome 5-year survival Weight
Myocardial infarction [34] 79.2 % 0.5
Ischemic stroke [35] 42.0 % 1.0
Hemorrhagic stroke [35] 42.0 % 1.0
Gastrointestinal bleeds [36] 45.5 % (3-year) 1.0
Colorectal cancer [37] 65.2 % 0.5
Biliary cancer [37] 18.3 % 1.0
Esophageal cancer [37] 18.3 % 1.0
Gastric cancer [37] 30.3 % 1.0
Breast cancer [37] 89.6 % 0.5
Lung cancer [37] 18.0 % 1.0
Prostate cancer [37] 98.9 % 0.1
Hematological cancer [37] 48.5 –85.8 % 0.5
Pancreatic cancer [37] 7.9 % 1.0
Bladder cancer [37] 77.4 % 0.5
Gynecological cancer [37] 45.8 –81.6 % 0.5
Renal cancer [37] 73.6 % 0.5
These weights can be adjusted individually on [http://www.benefit-harm-
balance.com]
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Construction of Benefit-Harm Charts
Similar to cardiovascular risk prediction charts, we con-
structed, for men and women separately, charts that in-
form individuals directly about the benefit-harm balance
of aspirin [http://www.benefit-harm-balance.com]. We
converted the probabilities that aspirin is net-beneficial
for each of the combinations of outcome risks into a
traffic light scheme. For results where ≥60 % of the
100,000 repetitions yielded a positive index (indicating
that aspirin has a positive benefit-harm balance), we
used the color green to indicate that the benefits of as-
pirin are likely to outweigh the harms. Accordingly, we
used orange for results where 40—60 % of the 100,000
repetitions yielded a positive index (to indicate some un-
certainty because the index is around 0) and red for re-
sults where <40 % of the 100,000 repetitions yielded a
positive index (indicating that the benefit-harm balance
is likely negative). The benefit-harm charts could include
many more combinations of outcome risks (for example,
for stroke and cancers), but we decided, for the sake of
usability, to restrict the benefit-harm charts to stratifica-
tion by sex, age, and 10-year risks of MI and severe GI
bleeds. But even if not represented visually, all analyses
included age- and sex-specific outcome risks for ische-
mic stroke, hemorrhagic stroke, the 12 cancers, and
death, as explained above.
Results
Illustrations of the Benefit-Harm Charts
Figure 1 and [http://www.benefit-harm-balance.com] il-
lustrate the Benefit-Harm Charts and explain how to use
them using the example of a 60-year old woman with
specific characteristics and preferences for the outcomes
(see caption of Fig. 1). Based on risk prediction models
that are calibrated for the region and population of the
patient (for example, Caucasian, Boston area, USA), the
10-year risks for MI and severe ischemic stroke are ele-
vated (6 % and 6 %, respectively). Her 10-year risk for
severe GI bleed is slightly elevated (5 %) because she
takes ibuprofen. The benefit-harm balance for this
woman can be located (Fig. 1) by the respective sex, age,
and risk categories for MI and severe GI bleeds. The red
color indicates that the benefit-harm balance does not
favor aspirin because the probability of overall benefit is
low.
Benefit-Harm Charts for women and men taking aspirin
for primary prevention of CVD and cancer
The Benefit-Harm Chart in Fig. 2 illustrates how differ-
ent outcome risks and their combinations influence the
benefit-harm balance of low dose aspirin. The benefit-
harm balance differs greatly across the primary preven-
tion population. For example, there are many more men
with different combinations of outcome risks who are
likely to benefit from low dose aspirin than women,
which is explained by their different risks for MI, stroke,
and cancers. It is important to note that the Benefit-
Harm Charts presented here focus on very low up to
moderately high risks for MI (0–25 %) and severe GI
bleeds (0–15 %), which covers a large proportion of a
general population [40]. It does not include 10-year
risks of severe GI bleeds above 15 %. If the 10-year
risks of severe GI bleeds are above 20 or 30 % (in
elderly men and women who experienced gastric ul-
cers in the past [41]), the benefit-harm balance be-
comes unfavorable again since the number of excess
severe GI bleeds under aspirin is high. Within women
and men, age is a strong determinant of the benefit-
harm balance with more overall benefit as age in-
creases). Also, the higher the risk of MI and the
lower the risk for severe GI bleeds, the more likely is
an overall benefit of aspirin.
Figure 3 shows the impact of using different weights
for the outcomes. The upper Benefit-Harm Chart shows
the benefit-harm balances for women using weights that
reflect the 5-year survival rates of the 16 outcomes
(Table 2). Assume now that these women consider a se-
vere stroke and cancers with 5-year survival rates <50 %
(very severe cancers) to be the most important out-
comes by far (100 on a scale from 0–100), followed
by cancers with 5-year survival rate between 50 and
90 % (severe cancers, 70) and MI and severe GI
bleeds (both 60), while cancers with 5-year survival
rates >90 % (moderately severe cancers, 10) are con-
sidered less important. The lower Benefit-Harm Chart
shows that low dose aspirin is likely to be beneficial
for more individuals since less weight is put on severe
GI bleeds. This example shows that preferences have
a large impact on the benefit-harm balance of low
dose aspirin. The online tool [http://www.benefit-harm-
balance.com] offers the opportunity to assess how the
benefit-harm balance changes according to individual
preferences.
Discussion
In this article, we conducted quantitative benefit-harm
assessments of low dose aspirin for primary prevention
of cardiovascular disease and cancer and we introduced
our Benefit-Harm Charts that visualize the results for
individuals. Our approach shows how two current lim-
itations of guidelines on low dose aspirin, that is, sep-
arate recommendations for cardiovascular disease and
cancer and population-based rather than more granu-
lated recommendations, could be overcome. Besides
the large impact of age and sex, the Benefit-Harm
Charts show that individuals will derive a certain net
benefit from aspirin depending not only on the risk
for cardiovascular disease and severe GI bleeds but
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also on the importance attributed to different benefit
and harm outcomes. The Benefit-Harm Charts may
support policy and guideline developers and also regu-
latory agencies in making more finely granulated rec-
ommendations and decisions. In addition, the Benefit-
Harm Charts can inform questions across diseases that
share a common preventive or therapeutic intervention.
Patients and physicians may be able to make individual-
ized treatment decisions based on combinations of out-
come risks and preferences.
Going beyond the simple approaches for benefit-harm
assessment
Estimating the benefit-harm balance is challenging for
many health care decisions because so many factors
need to be considered. Currently physicians and individ-
uals have to either simplify the task and use approaches
like the numberneeded totreat or number needed to
harm or not use a quantitative approach to assess
benefit-harm balance at all. Table 1 shows how guide-
lines result in different recommendations when using a
Fig. 1 Benefit-Harm Chart for low dose aspirin on [http://www.benefit-harm-balance.com]. The Benefit-Harm Charts inform about the benefit-harm
balance of low dose aspirin based on a patient’s risk profile. Benefit outcomes are (prevented) MI, severe ischemic stroke, and cancers, and harm
outcomes are (excess) severe GI bleed and severe hemorrhagic stroke. In the first step the risk profile of an individual is determined using risk factors
for the benefit and harm outcomes. Ideally, and to facilitate risk prediction, a computer processes the information on risk factors saved in the electronic
patient chart and provides the 10-year risk estimates. In this example, the 60-year old woman has a 10-year risk of 6 % for MI, 6 % for severe ischemic
stroke, 0.03 % for hemorrhagic stroke, 5 % for severe GI bleed (non-smoker, high blood pressure treated with atenolol tablet 50 mg per
day, no diabetes, no history of gastric ulcer, no atrial fibrillation, no left-ventricular hypertrophy but chronic lower back pain; systolic blood
pressure 145 mm Hg, total cholesterol 170 mg/dL, HDL cholesterol 55 mg/dL, takes ibuprofen tablet 200 mg twice a day. She eats vegetables regularly
and is physically active. There is no prior history of colorectal cancer in her family). Using the online calculator [http://www.benefit-harm-balance.com]
the Benefit-Harm Chart shows for specific outcome preferences (rulers on top) and for each combination of outcome risks (four 5x5 tables)
the probability that aspirin provides more benefits than harms (red colored cells <40 % of the 100,000 repetitions with index >0, yellow
colored cells 40–60 %, and green colored cells >60 % probability). For the 60-year old woman, the Benefit-Harm Chart shows that she is
likely to experience more harms than benefits from aspirin
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simplified or no approach to estimate the benefit-harm
balance. In contrast, comprehensive quantitative benefit-
harm assessments that consider all relevant factors that
have an impact on the benefit-harm balance allow for
testing the impact of different assumptions (such as
preferences) on the benefit-harm balance. To bridge the
gap between population-based estimates of the benefit-
harm balance (that focus on very few and averaged com-
binations of outcome risks) and individual preventive
counseling, quantitative benefit-harm assessments can
be repeated thousands of times for any possible risk pro-
file and preferences for outcomes, and the results can be
visualized through Benefit-Harm Charts. Based on
Benefit-Harm Charts it becomes easier to issue more
nuanced recommendations that reduce over- and under-
use of interventions. Such an approach could address
the current lack of systematic and transparent ap-
proaches to estimate the balance of benefits and harms
during the development of many guidelines and reduce
disagreement among guidelines [12].
However, some simplifications are currently necessary
when Benefit-Harm Charts are developed. For example,
we repeated the benefit-harm analyses “just” for women
and men and for four age categories and 25 combina-
tions of outcome risks for MI and GI bleeds (thus
2*4*25 = 200 different profiles). Thus we simplified this
second step by not repeating the analyses for any com-
bination of the 16 outcome risks but just for combina-
tions of sex, age, and outcome risks for MI and severe
GI bleeds, all of which have a substantial impact on the
benefit-harm balance of aspirin. For a visual and real-time
display (as on [http://www.benefit-harm-balance.com])
such simplifications are (currently) necessary. One could
also produce more individualized Benefit-Harm Charts
where different outcome risks are considered for all out-
comes or where the benefit-harm balance would be
Fig. 2 Benefit-Harm Chart for low dose aspirin for women and men. The Benefit-Harm Charts show the benefit-harm balance for four age categories
and, within age categories, for 25 different combinations of 10-year risks for MI and severe GI bleeds. A comparison between women and men (for
example, using age category 55–64 years) suggests that more men are likely to benefit from low dose aspirin than women. It is important to note that
the Benefit-Harm Charts presented here focus on very low up to moderately high risks for MI (0–25 % 10-year risk) and severe GI bleeds (0–15 %
10-year risk). If the 10-year risks of severe GI bleeds are above 20 or 30 % (in elderly men and women who experienced gastric ulcers in the past [41]),
the benefit-harm balance becomes unfavorable again since the number of excess severe GI bleeds under aspirin is high
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calculated even for one individual. It is challenging to
make the simulations so fast that the user can obtain a
real-time estimate of his or her (fully) individual benefit-
harm balance.
Moving guidelines forward
The Benefit-Harm Charts show that a substantial pro-
portion of the population is likely to benefit from low
dose aspirin for primary prevention of cardiovascular
disease and cancer. For example, a large proportion of
the general population has a low 10-year risk (<3 %) for
severe GI bleeds [40, 41]. Assuming the weights used for
Fig. 2, men of all four age classes and at 10-year risks for
severe GI bleeds of <10 % (no previous gastric ulcer, no
nonsteroidal anti-inflammatory agents [41]) are likely to
benefit from aspirin irrespective of their risk of MI. Eld-
erly women with at least moderately increased risk of
MI are also likely to benefit from aspirin. Even when as-
suming that the proportion of men and women changes
if outcomes are weighted differently, a substantial pro-
portion of men and women are likely to benefit.
The Benefit-Harm Charts show the limitations of
current guidelines: The recommendations are not granu-
lar enough to accommodate the great variation of the
benefit-harm balance of aspirin across the population.
Guidelines use few parameters to guide individualized
prevention and do not base their recommendations on
quantitative benefit-harm assessments except for the
Fig. 3 Impact of preferences on the benefit-harm balance. The two figures show the impact of putting different weights on the outcomes. In the
upper Benefit-Harm Chart severe gastrointestinal bleeds are weighted substantially more than in the lower Benefit-Harm Chart. For more scenarios
that reflect different preferences and outcome risks, refer to [http://www.benefit-harm-balance.com]
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USPSTF. As a consequence, there is a risk for under-
and overtreatment. Also current guidelines are likely to
underestimate the overall benefit from aspirin because
they focus on cardiovascular disease and cancer separ-
ately. Thereby, the same harms are counted twice (in the
cardiovascular and in the cancer guidelines against pre-
vented outcomes). The benefit-harm analyses and the
Benefit-Harm Charts presented here thus support the
idea of combining outcomes across disease areas if they
are prevented or treated by the same intervention [22].
Research needs
Although the Benefit-Harm Charts may appear attract-
ive, substantial research is still needed to bring them to
practice. For example, to consider the importance indi-
viduals assign to outcomes, preference-eliciting tools
need to be developed that are easily understood by indi-
viduals and implementable. Standard methods such as
standard gamble or time trade-off are complicated for
respondents and unrealistic for use in a practice setting
[42]. Best-worst scaling, which requires individuals to
repeatedly choose one outcome over another, pictorial
representations of illness, or some more informal tech-
niques are likely to be preferable [43–45]. In addition,
the presentation format of the Benefit-Harm Charts
needs to be tested using qualitative and quantitative re-
search [46]. Also, the impact of using Benefit-Harm
Charts on the decision-making process must be assessed
through trials, as is common for decision aids [47]. Fi-
nally, outcome risks, evidence on treatment effects, and
preferences may change over time. For example, there
are ongoing studies (ASPREE, ARRIVE, ASCEND,
ACCEPT-D) that assess the effects of aspirin in diverse
settings and populations as well as cost effectiveness
[48, 49]. Technically, it is not difficult to update
benefit-harm analyses such as the ones presented here
with additional evidence. But an important question
is how to organize such updates efficiently so that de-
cision makers can always rely on up-to-date Benefit-
Harm Charts. The use of modern information and
computing technology may prove valuable to support
an update process where, for example based on a
Bayesian framework, the additional evidence adds to
existing benefit-harm assessments and Benefit-Harm
Charts.
Strengths and limitations of study
We did not perform extensive sensitivity analyses as
commonly reported for quantitative benefit-harm ana-
lyses [24, 25, 50, 51] but provided an example for how
the choice of weights impacts the benefit-harm balance
(Fig. 2). The Gail/NCI approach can easily accommodate
such sensitivity analyses that consider different weights
[http://www.benefit-harm-balance.com], heterogeneity of
treatment effects, or a greater number of outcomes.
Such sensitivity analyses could also consider recent in-
sights into the time-varying effects of aspirin, which may
not show beneficial effects until at least 3 years after the
start of use, but whose benefits may be sustained for sev-
eral years even after cessation in long-term users [52].
Second, we assumed a simplified decision-making con-
text, where we did not consider additional conditions,
(for example, chronic lung disease), treatments (such as
proton pump inhibitors), or events during the 10 years
of prevention (for example, gastrointestinal bleed) that
may influence the risk profile or the propensity of taking
aspirin. Finally, we refrained from making recommenda-
tions about which prediction models to use and from
making recommendations for or against low dose as-
pirin, since the necessary judgments needed for develop-
ing recommendations in a guideline depend on more
factors than the ones we considered here [8, 9].
Conclusion
Extensive quantitative benefit-harm analyses for many
different combinations of outcome risks go well beyond
benefit-harm assessments made by policy makers, regu-
lators, or guideline developers that are often made for
entire populations only and not based on quantitative
benefit-harm analyses. The example of low dose aspirin
for primary prevention of cardiovascular disease and
cancer shows that it may be time for guideline devel-
opers to provide combined recommendations for differ-
ent diseases that may be prevented or treated by the
same intervention. Visualization of results by Benefit-
Harm Charts provides a novel way to make more finely
granulated policy decisions and recommendations but
also to inform individualized decisions on interventions.
This approach may avoid some of the simplifications
made by current regulatory process and guidelines,
which carry greater risk of over- and undertreatment.
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